Request Demo
Boehringer’s obesity drug shows efficacy for liver disease
27 Feb 2024
Phase 2Fast TrackClinical Result
Boehringer is also investigating survodutide’s efficacy in obesity in five clinical trials. Credit: Michael Vi via Shutterstock.
Boehringer Ingelheim’s glucagon/Gsurvodutideor dual agonistobesityutide has demonstrated efficacy for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease connected with other cardiovascular, renal, and metabolic conditions.
Boehringer IngelheimNCTglucagon)GLP-1 receptorry endpoint, wsurvodutideof patients treated with survodmetabolic dysfunction-associated steatohepatitis (MASH) witliver diseaseening of their fibrosis stages, compared to 18.2% of patients who took the placebo.
Boehringer Ingelheim’s candidate stands out from other GLP-1 receptor agonists in that it also tsurvodutidehormone glucagon. Simultaneously activating thMASHtwo key gut hormone receptors cofibrosisntially produce more efficacious results than the current single-hormone agonists, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, the two main players for obesity.
Boehringer Ingelheiml, secondary endpoints evaluating rGLP-1 receptoribrosis and lower liver fat content, as measured by a specific magnetic resonance imaging (MRI) gut hormone receptorsmet.Novo NordiskEliLillyZepboundobesity
Boehringer, in partnership with the Danish biotech Zealand, isliver fibrosis survodutide in five clinical trials for obesity, including three—SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-CVOT—which were kicked off in May 2023.
Boehringermneal signs agreement with Zambon for Parkinson’s disease therapysurvodutideobesity
Biogen reAmneal EMA CHMP recommendatiZambon ALS Parkinson’s disease
The booming obesity market is forecast to reach $37.1bn in the seven major markets (US, France, Germany, Italy, Spain, UK and Japan) in 2031, according to a report on GlobalData’s Pharma Intelligence Center.
In June 2021, the US Food and Drug Administration (FDA) granted fast track designation for survodutide, with the European Medicines Agency (EMA) following suit, granting access to the Priority Medicine (PRIME) scheme for MASH with fibrosis in November 2023. The scheme enables earlier access to treatments that targets conditions with an unmet medical need.
In the 26 Feobesityannouncement accompanying the data, head of human pharma at Boehringer Carinne Brouillon said: “These MASH results show survodutide has potential to become a best-in-class treatment, and we believe its true differentiator is the action of the glucagon receptor agonism which works directly on the liver.”
Earlier this year, Boehringer reinfoPharmaceutical Technology entering into a multi-target collaboration with Suzhou Ribo Life Science and Ribocure Pharmaceuticals (Ribo) targeting the condition in a deal worth $2bn. This collaboration comes six years after Boehringer joined forces with Dicerna Pharmaceuticals to discover and develop new therapeutics using Dicerna’s GalXC technology platform, for the treatment of liver diseases including MASH.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.